Nehal Aly Hamdy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nehal Aly Hamdy has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Issa Fakhr
Applied Organic Chemistry Department, National Research Centre, Dokki, Cairo, Egypt
12 shared publications - Hatem A. Abdel-Aziz
Department of Applied Organic Chemistry, National Research Center, Dokki, Cairo 12622, Egypt
9 shared publications - Amira M. Gamal-Eldeen
Clinical Laboratory Sciences Department, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia
6 shared publications Issa M. I. Fakhr
Applied Organic Chemistry Department Chemical Industries Research Institute, National Research Centre Cairo Egypt
4 shared publications- Ahmad Mahmoud Farag
Department of Chemistry, Faculty of Science, Cairo University, Giza 12613, Egypt
3 shared publications Eman Kh. Hamza
Applied Organic Chemistry Department Chemical Industries Research Institute, National Research Centre Cairo Egypt
3 shared publications
Latest Publications
- 24 October 2025
- Published by Wiley in Journal of Heterocyclic Chemistry
- Vol. 63 (2) , 209-227
Novel Pyrazoline and Pyrazoline–Thiazole Derivatives Linked to Tetrahydronaphthalene Ring: Synthesis, Anticancer Evaluation, VEGFR ‐2 Inhibition Activity, and Molecular Docking Study
A new series of pyrazoline and pyrazoline–thiazole derivatives conjugated with tetralin ring 5a, b–19 was created starting with the chalcones 3a , b . The new compounds were tested as potential anticancer agents on three human cancer cell lines (HCT‐116, HepG‐2, and MCF‐7) and one human normal cell line (BJ‐1). The Compounds 5a , b , 7a , 9a , b , 10 , 13a , d , and 16b were identified as strong candidates against the MCF‐7 cell line (IC 50 = 2.0 ± 0.1–5.6 ± 0.2 μM), where all the compounds exhibited significant activity against the HCT‐116 cell line (IC 50 = 2.8 ± 0.1–6.5 ± 0.5 μM). Compounds 5b, 9b , and 10 were chosen to study VEGFR‐2 inhibitors in comparison with sorafenib (IC 50 = 2.9 ± 0.08, 8.6 ± 0.41, 1.1 ± 0.04, and 0.2 ± 0.01 nM, respectively). A molecular docking study was conducted to ascertain the latter compounds' binding interactions with VEGFR‐2 kinase.
- 24 October 2025
- Published by Wiley in Journal of Heterocyclic Chemistry
- Vol. 63 (2) , 209-227
Novel Pyrazoline and Pyrazoline–Thiazole Derivatives Linked to Tetrahydronaphthalene Ring: Synthesis, Anticancer Evaluation, VEGFR ‐2 Inhibition Activity, and Molecular Docking Study
A new series of pyrazoline and pyrazoline–thiazole derivatives conjugated with tetralin ring 5a, b–19 was created starting with the chalcones 3a , b . The new compounds were tested as potential anticancer agents on three human cancer cell lines (HCT‐116, HepG‐2, and MCF‐7) and one human normal cell line (BJ‐1). The Compounds 5a , b , 7a , 9a , b , 10 , 13a , d , and 16b were identified as strong candidates against the MCF‐7 cell line (IC 50 = 2.0 ± 0.1–5.6 ± 0.2 μM), where all the compounds exhibited significant activity against the HCT‐116 cell line (IC 50 = 2.8 ± 0.1–6.5 ± 0.5 μM). Compounds 5b, 9b , and 10 were chosen to study VEGFR‐2 inhibitors in comparison with sorafenib (IC 50 = 2.9 ± 0.08, 8.6 ± 0.41, 1.1 ± 0.04, and 0.2 ± 0.01 nM, respectively). A molecular docking study was conducted to ascertain the latter compounds' binding interactions with VEGFR‐2 kinase.
- 25 March 2024
- Published by Egyptian Knowledge Bank in Egyptian Journal of Chemistry
Synthesis, anticancer properties, and molecular modeling of novel thiazolyl-pyrazolone derivatives conjugated with tetrahydronaphthalene as anticancer agents with potential VEGFR-2 inhibition activity
The synthesis of 4-arylidene-3-methyl-1-(4-(5,6,7,8-tetrahydronaphthalen-2-yl)thiazol-2-yl)-1H-pyrazol-5(4H)-ones was described as a successful multi-component condensation reaction. Thiazole and pyrazolone are simultaneously formed during the synthesis process, and an active methylene group is condensed with an aryl aldehyde using the Knoevenagel reaction. Some of the remarkable characteristics of this technique are quick reaction times, gentle environmental conditions, straightforward operation, streamlined purification, and acceptable yields. The newly synthesized compounds were assessed as anticancer agents on HCT-116, HepG-2, and MCF-7 human cancer cells and one human healthy cell line (BJ-1) using the LDH assay. The most active compounds were examined as VEGFR inhibitors. Moreover, a molecular docking study was conducted to identify the binding interactions of the most potent candidates (6e, 6g, and 6i), within the active sites of the Vascular Endothelial Growth Factor Receptor (VEGFR-2/KDR) kinase. Compounds 6e, 6g and 6i exhibited the most favorable binding interaction scores with the targeted enzyme. Furthermore, the bioassay results demonstrated that the three selected compounds (6e, 6g, and 6i) displayed highly promising activities by significantly inhibiting VEGFR-2 kinase at very low IC50 values compared to their cytotoxicity IC50 outcomes.
- 25 March 2024
- Published by Egyptian Knowledge Bank in Egyptian Journal of Chemistry
Synthesis, anticancer properties, and molecular modeling of novel thiazolyl-pyrazolone derivatives conjugated with tetrahydronaphthalene as anticancer agents with potential VEGFR-2 inhibition activity
The synthesis of 4-arylidene-3-methyl-1-(4-(5,6,7,8-tetrahydronaphthalen-2-yl)thiazol-2-yl)-1H-pyrazol-5(4H)-ones was described as a successful multi-component condensation reaction. Thiazole and pyrazolone are simultaneously formed during the synthesis process, and an active methylene group is condensed with an aryl aldehyde using the Knoevenagel reaction. Some of the remarkable characteristics of this technique are quick reaction times, gentle environmental conditions, straightforward operation, streamlined purification, and acceptable yields. The newly synthesized compounds were assessed as anticancer agents on HCT-116, HepG-2, and MCF-7 human cancer cells and one human healthy cell line (BJ-1) using the LDH assay. The most active compounds were examined as VEGFR inhibitors. Moreover, a molecular docking study was conducted to identify the binding interactions of the most potent candidates (6e, 6g, and 6i), within the active sites of the Vascular Endothelial Growth Factor Receptor (VEGFR-2/KDR) kinase. Compounds 6e, 6g and 6i exhibited the most favorable binding interaction scores with the targeted enzyme. Furthermore, the bioassay results demonstrated that the three selected compounds (6e, 6g, and 6i) displayed highly promising activities by significantly inhibiting VEGFR-2 kinase at very low IC50 values compared to their cytotoxicity IC50 outcomes.
- 31 January 2023
- Published by Taylor & Francis in Synthetic Communications
- Vol. 53 (4) , 298-315
Synthesis of novel heterocyclic compounds bearing tetralin moiety of potential anticancer activity targeting the intrinsic apoptotic pathway
This study deals with the readily reaction of the enaminone derivative 3 with different reagents to give the corresponding pyrazolo[3,4-b]pyridine, pyrazolo[1,5-a]pyrimidine, pyrazole, pyrazolopyridazine, dienamide, and pyranone derivatives. In-vitro cytotoxic screening was performed for all analogs against several human cancer cell lines. Compound 21 showed significant anti-breast cancer activity and a safety profile against the normal human cell lines (BJ-1). Furthermore, compound 21 was chosen as a representative example to study its potential apoptotic mechanism in the MCF-7 cancer cell line. It enhanced DNA fragmentation alongside its characteristic effect on tubulin polymerization. In addition, compound 21 up-regulated the pro-apoptotic Bax protein, decreased the Bcl-2 anti-apoptotic protein, and increased p53 and Caspase-7 levels confirming its mitochondrial intrinsic apoptotic activation. Graphical Abstract
- 31 January 2023
- Published by Taylor & Francis in Synthetic Communications
- Vol. 53 (4) , 298-315
Synthesis of novel heterocyclic compounds bearing tetralin moiety of potential anticancer activity targeting the intrinsic apoptotic pathway
This study deals with the readily reaction of the enaminone derivative 3 with different reagents to give the corresponding pyrazolo[3,4-b]pyridine, pyrazolo[1,5-a]pyrimidine, pyrazole, pyrazolopyridazine, dienamide, and pyranone derivatives. In-vitro cytotoxic screening was performed for all analogs against several human cancer cell lines. Compound 21 showed significant anti-breast cancer activity and a safety profile against the normal human cell lines (BJ-1). Furthermore, compound 21 was chosen as a representative example to study its potential apoptotic mechanism in the MCF-7 cancer cell line. It enhanced DNA fragmentation alongside its characteristic effect on tubulin polymerization. In addition, compound 21 up-regulated the pro-apoptotic Bax protein, decreased the Bcl-2 anti-apoptotic protein, and increased p53 and Caspase-7 levels confirming its mitochondrial intrinsic apoptotic activation. Graphical Abstract
- 19 November 2019
- Published by Wiley in Journal of Heterocyclic Chemistry
- Vol. 57 (1) , 182-196
Synthesis and in vitro evaluation of novel tetralin‐pyrazolo[3,4‐b]pyridine hybrids as potential anticancer agents
New hybrids of tetralin‐pyrazolo[3,4‐b]pyridine were synthesized in good yields. The structures of newly synthesized compounds were confirmed by IR, NMR, MS, and elemental analyses. Some of the new compounds were in vitro evaluated as antiproliferative candidates against two human cancer cell lines (HCT116 and MCF‐7). Most of the examined derivatives showed promising anticancer activity.
- 19 November 2019
- Published by Wiley in Journal of Heterocyclic Chemistry
- Vol. 57 (1) , 182-196
Synthesis and in vitro evaluation of novel tetralin‐pyrazolo[3,4‐b]pyridine hybrids as potential anticancer agents
New hybrids of tetralin‐pyrazolo[3,4‐b]pyridine were synthesized in good yields. The structures of newly synthesized compounds were confirmed by IR, NMR, MS, and elemental analyses. Some of the new compounds were in vitro evaluated as antiproliferative candidates against two human cancer cell lines (HCT116 and MCF‐7). Most of the examined derivatives showed promising anticancer activity.
- 12 March 2018
- Published by Elsevier in Letters in Drug Design & Discovery
- Vol. 15 (4) , 336-346
Synthesis, Anti-Methicillin-resistant S. aureus (MRSA) Evaluation, Quantitative Structure-Activity Relationship and Molecular Modeling Studies of Some Novel Bis-indoles as Prospective MRSA Pyruvate Kinase Inhibitors
MRSA is a gram positive pathogen resistant to methicillin and other beta-lactam antibiotics, including penicillin, oxacillin, and declooxacillin. Statistical data suggest that as many as 19,000 people per year die from MRSA in the USA. Prudent use of existing drugs, coupled with the development of new antibacterial agents has been suggested as a way to combat the public health burden, posed by MRSA. In this work, about 60 compounds of bis-indoles (diindolylmethanes and diindolylmethenes) was synthesized and screened as antibacterial agents against S. aureus and methicillin-resistant S. aureus (MRSA). The quantitative structure-activity relationships (QSAR) of the com-pounds were also carried out in this work. Good numbers of the compounds appear to be good antibiotic candi-dates against MRSA. The modelled complexes of S. aureus pyruvate kinase (PK) and the active compounds indi-cate that these bis-indole candidates fit perfectly in the binding groove between two monomers of PK. The com-pounds are predicted to have H-bond and steric interactions with important amino acid residues. The current study may leads to discover a new prospective anti-MRSA candidates.
- 12 March 2018
- Published by Elsevier in Letters in Drug Design & Discovery
- Vol. 15 (4) , 336-346
Synthesis, Anti-Methicillin-resistant S. aureus (MRSA) Evaluation, Quantitative Structure-Activity Relationship and Molecular Modeling Studies of Some Novel Bis-indoles as Prospective MRSA Pyruvate Kinase Inhibitors
MRSA is a gram positive pathogen resistant to methicillin and other beta-lactam antibiotics, including penicillin, oxacillin, and declooxacillin. Statistical data suggest that as many as 19,000 people per year die from MRSA in the USA. Prudent use of existing drugs, coupled with the development of new antibacterial agents has been suggested as a way to combat the public health burden, posed by MRSA. In this work, about 60 compounds of bis-indoles (diindolylmethanes and diindolylmethenes) was synthesized and screened as antibacterial agents against S. aureus and methicillin-resistant S. aureus (MRSA). The quantitative structure-activity relationships (QSAR) of the com-pounds were also carried out in this work. Good numbers of the compounds appear to be good antibiotic candi-dates against MRSA. The modelled complexes of S. aureus pyruvate kinase (PK) and the active compounds indi-cate that these bis-indole candidates fit perfectly in the binding groove between two monomers of PK. The com-pounds are predicted to have H-bond and steric interactions with important amino acid residues. The current study may leads to discover a new prospective anti-MRSA candidates.
- 1 April 2014
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 77, 323-333
Induction of intrinsic apoptosis pathway in colon cancer HCT-116 cells by novel 2-substituted-5,6,7,8-tetrahydronaphthalene derivatives
- 1 April 2014
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 77, 323-333
Induction of intrinsic apoptosis pathway in colon cancer HCT-116 cells by novel 2-substituted-5,6,7,8-tetrahydronaphthalene derivatives
- 5 January 2014
- Vol. 70 (6) , 987-1001
Synthesis, tumor inhibitory and antioxidant activity of new polyfunctionally 2-substituted 5,6,7,8-tetrahydronaphthalene derivatives containing pyridine, thioxopyridine and pyrazolopyridine moieties.
2-Acetyl-5,6,7,8-tetrahydronaphthalene (1) was allowed to react with different aromatic aldehydes to produce the cyanopyridones 2a and 2b, which were treated with phosphorous pentasulfide to afford the corresponding thioxopyridine derivatives 3a and 3b, respectively. The reaction of 3a and 3b with ethyl bromoacetate afforded the ester derivatives 4a and 4b, while their condensation with hydrazine hydrate gave the corresponding pyrazolopyridine derivatives 5a and 5b. The reaction of the precursor 2-amino-5,6,7,8-tetrahydronaphthalene (6) with ethoxy methylenemalonic ester led to the formation of aminomethylenemalonate derivative 7. Cyclization of 7 in boiling diphenyl ether gave the derivative - ethyl 6,7,8,9-tetrahydro-4-hydroxybenzo[g]-quinoline-3-carboxylate (8) which was hydrolyzed to produce the corresponding carboxylic acid analogue 9. Further reaction of 3a with 3-chloropropane-1,2-diol and/or iodomethane produced the corresponding nicotinonitrile derivatives 10 and 11. Hydrazinolysis of derivative 11 gave the hydrazinyl derivative 12. Moreover, chlorination of compound 2a with phosphorous oxychloride led to 2-chloro nicotinonitrile derivative 13, which was refluxed with various amines to form the corresponding derivatives 5a, 14 and 15. Treatment of the pyrazolopyridine compound 5a with formic acid and acetic anhydride afforded the corresponding formamide and acetamide analogues 16 and 17, while its reaction with DMF-DMA yielded the corresponding formimidamide derivative 18. The pyridopyrazolo[1,5-a]pyrimidine derivative 19 was obtained by cyclization of 5a with acetyl acetone. The antioxidant activity evaluation of the newly synthesized compounds showed that the pyrazolopyridine derivative 5a exhibited scavenging potency higher than that obtained by ascorbic acid. Tumor inhibitory activity screening revealed that derivatives 8 and 10 showed promising potency against the liver cancer cells (HepG-2) compared to doxorubicin as a reference drug.
- 5 January 2014
- Vol. 70 (6) , 987-1001
Synthesis, tumor inhibitory and antioxidant activity of new polyfunctionally 2-substituted 5,6,7,8-tetrahydronaphthalene derivatives containing pyridine, thioxopyridine and pyrazolopyridine moieties.
2-Acetyl-5,6,7,8-tetrahydronaphthalene (1) was allowed to react with different aromatic aldehydes to produce the cyanopyridones 2a and 2b, which were treated with phosphorous pentasulfide to afford the corresponding thioxopyridine derivatives 3a and 3b, respectively. The reaction of 3a and 3b with ethyl bromoacetate afforded the ester derivatives 4a and 4b, while their condensation with hydrazine hydrate gave the corresponding pyrazolopyridine derivatives 5a and 5b. The reaction of the precursor 2-amino-5,6,7,8-tetrahydronaphthalene (6) with ethoxy methylenemalonic ester led to the formation of aminomethylenemalonate derivative 7. Cyclization of 7 in boiling diphenyl ether gave the derivative - ethyl 6,7,8,9-tetrahydro-4-hydroxybenzo[g]-quinoline-3-carboxylate (8) which was hydrolyzed to produce the corresponding carboxylic acid analogue 9. Further reaction of 3a with 3-chloropropane-1,2-diol and/or iodomethane produced the corresponding nicotinonitrile derivatives 10 and 11. Hydrazinolysis of derivative 11 gave the hydrazinyl derivative 12. Moreover, chlorination of compound 2a with phosphorous oxychloride led to 2-chloro nicotinonitrile derivative 13, which was refluxed with various amines to form the corresponding derivatives 5a, 14 and 15. Treatment of the pyrazolopyridine compound 5a with formic acid and acetic anhydride afforded the corresponding formamide and acetamide analogues 16 and 17, while its reaction with DMF-DMA yielded the corresponding formimidamide derivative 18. The pyridopyrazolo[1,5-a]pyrimidine derivative 19 was obtained by cyclization of 5a with acetyl acetone. The antioxidant activity evaluation of the newly synthesized compounds showed that the pyrazolopyridine derivative 5a exhibited scavenging potency higher than that obtained by ascorbic acid. Tumor inhibitory activity screening revealed that derivatives 8 and 10 showed promising potency against the liver cancer cells (HepG-2) compared to doxorubicin as a reference drug.
- 30 August 2013
- Published by Wiley in ChemInform
- Vol. 44 (38)
ChemInform Abstract: Enaminone as Building Blocks in Organic Chemistry: A Novel Route to Polyfunctionally 2-Substituted 5,6,7,8-Tetrahydronaphthalenes and Their Antiviral Evaluation.
Enaminone (III) is used as starting material for a series of syntheses.
- 30 August 2013
- Published by Wiley in ChemInform
- Vol. 44 (38)
ChemInform Abstract: Enaminone as Building Blocks in Organic Chemistry: A Novel Route to Polyfunctionally 2-Substituted 5,6,7,8-Tetrahydronaphthalenes and Their Antiviral Evaluation.
Enaminone (III) is used as starting material for a series of syntheses.
- 26 August 2013
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 76 (9) , 1541-1547
In Vitro Pharmacological and Toxicological Effects of Norterpene Peroxides Isolated from the Red Sea Sponge Diacarnus erythraeanus on Normal and Cancer Cells
Eight cyclic peroxide norterpenoids, compounds 1–8, have been isolated and characterized from the Red Sea sponge Diacarnus erythraeanus, including two new norsesterterpene derivatives (3, 4). Among these metabolites, (−)-muqubilin A (5) (nine cell lines analyzed) and the new compounds 3 and 4 (seven cell lines analyzed) displayed mean IC50 growth inhibitory concentrations in vitro of in vitro growth inhibition. Quantitative video microscopy analysis carried out on (−)-muqubilin A-treated cells validated the data obtained by means of the MTT colorimetric assay, while flow cytometry analysis revealed ROS production but no induction of apoptosis in cancer cells.
- 26 August 2013
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 76 (9) , 1541-1547
In Vitro Pharmacological and Toxicological Effects of Norterpene Peroxides Isolated from the Red Sea Sponge Diacarnus erythraeanus on Normal and Cancer Cells
Eight cyclic peroxide norterpenoids, compounds 1–8, have been isolated and characterized from the Red Sea sponge Diacarnus erythraeanus, including two new norsesterterpene derivatives (3, 4). Among these metabolites, (−)-muqubilin A (5) (nine cell lines analyzed) and the new compounds 3 and 4 (seven cell lines analyzed) displayed mean IC50 growth inhibitory concentrations in vitro of in vitro growth inhibition. Quantitative video microscopy analysis carried out on (−)-muqubilin A-treated cells validated the data obtained by means of the MTT colorimetric assay, while flow cytometry analysis revealed ROS production but no induction of apoptosis in cancer cells.